Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Advances in Skin & Wound Care|July 18, 2024
Improving Wound Healing and Infection Control in Long-term Care with Bacterial Fluorescence ImagingMartha R Kelso, Mark Jaros
Journal of Wound Care|November 8, 2025
A comparative analysis of sharp debridement devices for biofilm management in hard-to-heal wounds: a clinical assessmentAndrew Rader, Jeffrey Niezgoda, Martha R Kelso, et al.
Journal of Wound Care|May 13, 2025
The hidden costs of limiting access: clinical and economic risks of Medicare's future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage DeterminationWilliam Tettelbach, David Armstrong, Jeffery Niezgoda, et al.
Current Medical Research and Opinion|October 28, 2015
Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 studyRoy Altman, Marc Hochberg, Allan Gibofsky, et al.
Journal of Alzheimer'S Disease : JAD|June 7, 2024
Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's DiseaseJack Taylor, Mark Jaros, Christopher Chen, et al.
Journal of Racial and Ethnic Health Disparities|April 11, 2023
Skin Pigmentation Impacts the Clinical Diagnosis of Wound Infection: Imaging of Bacterial Burden to Overcome Diagnostic LimitationsJonathan Johnson, Alton R Johnson, Charles A Andersen, et al.
Brain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJack Taylor, Paul Rolan, Mark Jaros, et al.
Brain Communications|December 15, 2022
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trialDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 13, 2011
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trialsNicola Coley, Sandrine Andrieu, Mark Jaros, et al.
Pageof 4